The proposed acquisition consideration represents an equity value of $2.4 billion and an enterprise value of $2.5 billion, Sumitovant Biopharma said in a statement.
(Reporting by Anirudh Saligrama in Bengaluru)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
300 JPY | -0.66% | -10.71% | -35.62% |
09/05 | Sumitomo Pharma Co., Ltd. agreed to acquire MELTz Business of MELTIN MMI Co., Ltd. | CI |
07/05 | Profit-Taking, China Outlooks Churn Asian Stock Markets | MT |
(Reuters) - Sumitovant Biopharma said on Sunday the company and its parent Sumitomo Pharma Co Ltd had submitted a non-binding offer to acquire Myovant Sciences Ltd.
The proposed acquisition consideration represents an equity value of $2.4 billion and an enterprise value of $2.5 billion, Sumitovant Biopharma said in a statement.
(Reporting by Anirudh Saligrama in Bengaluru)
1st Jan change | Capi. | |
---|---|---|
-35.62% | 76Cr | |
+38.69% | 73TCr | |
+33.10% | 60TCr | |
-4.49% | 36TCr | |
+20.24% | 33TCr | |
+2.12% | 28TCr | |
+15.75% | 24TCr | |
+7.99% | 21TCr | |
-5.36% | 21TCr | |
-0.35% | 16TCr |